# Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct02291237` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02291237](<https://clinicaltrials.gov/study/NCT02291237>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02291237

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 172 participants.

## Technical summary

Registry record NCT02291237. Randomized; quadruple masking; primary purpose treatment. Start 2015-02-05 (actual); primary completion 2017-01-20 (actual). Results posted on 2018-03-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 172 participants (enrolled count; ClinicalTrials.gov record NCT02291237, source copy `cardio:ctgov-nct02291237-2018-09-24`, retrieved 2026-10-26)
- Started: 2015-02-05 (actual) (ClinicalTrials.gov record NCT02291237, source copy `cardio:ctgov-nct02291237-2018-09-24`, retrieved 2026-10-26)
- Primary completion: 2017-01-20 (actual) (ClinicalTrials.gov record NCT02291237, source copy `cardio:ctgov-nct02291237-2018-09-24`, retrieved 2026-10-26)
- Completion: 2017-02-17 (actual) (ClinicalTrials.gov record NCT02291237, source copy `cardio:ctgov-nct02291237-2018-09-24`, retrieved 2026-10-26)
- Results first posted: 2018-03-22 (ClinicalTrials.gov record NCT02291237, source copy `cardio:ctgov-nct02291237-2018-09-24`, retrieved 2026-10-26)
- Countries: United States; Australia; France; Germany; Israel; Italy; Netherlands; United Kingdom (ClinicalTrials.gov record NCT02291237, source copy `cardio:ctgov-nct02291237-2018-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02291237-2018-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
- Acronym: LIBERTY-HCM
- Condition: Hypertrophic Cardiomyopathy
- Intervention (Drug): Eleclazine
- Intervention (Drug): Placebo
- Lead sponsor: Gilead Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Gilead Sciences (`cardio:org-gilead-sciences`)

## Provenance

Content hash: d1fa4bf12e7569524f00ea9909bdb6805f6a3a1a03b2b3d59242c9f49f62d5b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
